Clinical trials: Breast Cancer, Male
Bone Cancer, Bone Metastases
Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma
The goal of this study is to collect comparative data on safety and efficacy of MR Guided Focused Ultrasound and External Beam Radiation for treatment of metastatic bone tumors or multiple myeloma.
- Conditions
- Bone Cancer, Bone Metastases, Pain
- Trial name
- NCT01091883
- Testing
- Exablate treatment, Radiation
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- InSightec
Breast Cancer, Colorectal Cancer
Physical Training and Cancer-a Multicenter Clinical Trial
Excessive tiredness (fatigue) is a common problem in cancer patients and can affect quality of life negatively. There is limited knowledge about the physical mechanisms that cause fatigue, and there is no medical treatment.
- Conditions
- Breast Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- Phys-Can (NCT02473003)
- Testing
- high intensity exercise, low/medium intensity exercise, Behavioral medicine strategies
- Volunteers
- 600 people
- Sponsor
- Uppsala University
Breast Cancer, Glioma
A Study of Gene Polymorphisms and Normal Tissue Radiation Injury in Patients Treated for Breast, Prostate, Brain, Lung, and Head and Neck Cancers
This study will examine, for the first time, the independent contribution of a patient's own genetic makeup to the development of post-radiation complications, permitting the future development of predictive tests to avoid…
- Conditions
- Breast Cancer, Glioma, Prostate Cancer, Carcinoma, Squamous Cell
- Trial name
- NCT00122239
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- AHS Cancer Control Alberta
Cancer, Breast, Cancer, Lung
Patient Education Videos to Improve Patients' Experience During Radiotherapy Treatment: a National Project
Patients often base their information on the experiences of other patients or on information they find on the internet. This information is in many cases incorrect, outdated or not applying to the patient's situation.
- Conditions
- Cancer, Breast, Cancer, Lung, Cancer Prostate, Cancer Head Neck
- Trial name
- NCT06152419
- Testing
- Questionnaire
- Where
- Belgium
- Volunteers
- 25 people
- Sponsor
- University Hospital, Ghent
Ovarian Cancer, Fallopian Tube Cancer
Choices About Genetic Testing And Learning Your Risk With Smart Technology
This study seeks to enhance genetic education and increase the uptake of genetic testing for hereditary cancer risk among cancer survivors.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Breast Cancer
- Trial name
- CATALYST (NCT06184867)
- Testing
- Relational Agent (RA), Enhanced Usual Care (EUC)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Uterine Cancer, Rectal Cancer
Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women
Female patients with early onset (<50 years old) pelvic malignancies such as uterine and rectal cancers are rising in incidence, which often requires pelvic radiation; many of these patients are premenopausal and at a high risk…
- Conditions
- Uterine Cancer, Rectal Cancer, Colon Cancer, Breast Cancer
- Trial name
- OvAR-Y (NCT06904365)
- Testing
- HyperSight cone beam computed tomography (CBCT) scan, ETHOS 2.0
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Washington University School of Medicine
Brain Metastases, Adult
Neoadjuvant Immunotherapy in Brain Metastases
The purpose of this phase 2 study is to assess the feasibility and efficacy of neoadjuvant immunotherapy in patients with previously untreated, surgically-resectable, solid tumor brain metastases.
- Trial name
- NCT04434560
- Testing
- Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Sarah Sammons, MD
Lung Cancer, Breast Cancer
Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.
The study aim to investigate the relationship between cutaneous adverse events and quality of life in patients taking immune check point inhibitor or cyclin-dependent kinase (CDK) 4 and 6 inhibitors by two steps.
- Conditions
- Lung Cancer, Breast Cancer, Kidney Cancer, Bladder Cancer
- Trial name
- SkinHealth (NCT05878964)
- Testing
- EQ-5D-5L questionnaire, FACT-G (Functional Assessment of Cancer Therapy - General), FACT-EGFRI-18 (Functional Assessment of Cancer Therapy - Epidermal Growth Factor Inhibitors 18 Item)
- Where
- Italy
- Volunteers
- 420 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Breast Cancer
Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00852332
- Testing
- Curcumin, Taxotere
- Where
- France
- Volunteers
- 42 people
- Sponsor
- Centre Jean Perrin
Breast Neoplasms, Male
MALE Mamm Organoids
It is believed that the use of organoids derived from male breast tumors can be of fundamental support for the definition of the molecular mechanisms underlying the onset of the tumor.
- Trial name
- NCT06786663
- Where
- Italy
- Volunteers
- 7 people
- Sponsor
- Regina Elena Cancer Institute
Breast Cancer
Chemotherapy Combined With Gene Therapy in Treating Patients Who Have Stage III or Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Inserting the p53 gene into the tumor may increase the effectiveness of a chemotherapy drug by making tumor…
- Trial name
- NCT00044993
- Testing
- Ad5CMV-p53 gene, docetaxel, doxorubicin hydrochloride
- Where
- United States
- Sponsor
- Introgen Therapeutics
Breast Cancer
Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00323063
- Testing
- gemcitabine hydrochloride, imatinib mesylate
- Where
- 9 sites in United States
- Volunteers
- 49 people
- Sponsor
- Rutgers, The State University of New Jersey
Breast Cancer, Colorectal Cancer
Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer
RATIONALE: Measuring levels of transforming growth factor-beta (TGF-beta) in the blood of patients with epithelial cancers (head and neck, lung, breast, colorectal, and prostate) may help doctors predict how patients will respond…
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00897793
- Testing
- venipuncture, radiation therapy
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Breast Cancer
Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer
RATIONALE: Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing…
- Trial name
- NCT00054470
- Testing
- trastuzumab, tipifarnib
- Sponsor
- The University of Texas Health Science Center at San Antonio
Breast Cancer
PET Scans in Assessing Response To Treatment in Patients Receiving Hormone Therapy or Trastuzumab for Breast Cancer
RATIONALE: Diagnostic procedures, such as PET scans, may help in learning how well hormone therapy and trastuzumab work to kill breast cancer cells and allow doctors to plan better treatment.
- Trial name
- NCT00362973
- Testing
- laboratory biomarker analysis, needle biopsy, positron emission tomography
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- University of Washington
Breast Cancer, Prostate Cancer
111 Indium CHX-A DTPA Trastuzumab (Indium-Herceptin) for Imaging Breast Cancer
Background: Some breast cancer cells have specific proteins (receptors) on their surface that make the tumor grow faster than normal cells. One of these receptors is called HER2/neu.
- Conditions
- Breast Cancer, Prostate Cancer, Lung Cancer, Colon Cancer
- Trial name
- NCT01445054
- Testing
- 111Indium CHX-A
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast Cancer
RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor.
- Trial name
- NCT00030537
- Testing
- erlotinib hydrochloride
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Solid Neoplasm, Stage III Pancreatic Cancer
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
This phase I trial studies the side effects and best dose of palbociclib with cisplatin or carboplatin in treating patients with solid tumors that have spread to other places and usually cannot be cured or controlled with…
- Conditions
- Solid Neoplasm, Stage III Pancreatic Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-Small Cell Lung Cancer
- Trial name
- NCT02897375
- Testing
- Carboplatin, Cisplatin, Palbociclib
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Emory University
Breast Cancer
Immune Response in Patients Who Have Undergone Vaccine Therapy for Stage III or Stage IV Breast Cancer That Overexpresses HER2
RATIONALE: Studying the immune response to a vaccine made from HER2/neu protein may help doctors plan better treatment for patients with breast cancer that overexpresses HER2.
- Trial name
- NCT00363012
- Testing
- HER-2/neu intracellular domain protein, flow cytometry, immunohistochemistry staining method
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- University of Washington
Colorectal Cancer, Lung Cancer
Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors
This is a Phase I, multi-center study of GM-CT-01, which has been shown to increase the anti-tumor activity of 5-fluorouracil in mice.
- Conditions
- Colorectal Cancer, Lung Cancer, Breast Cancer, Head and Neck Cancer
- Trial name
- NCT00054977
- Testing
- GM-CT-01, 5-fluorouracil
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Galectin Therapeutics Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.